Erythromycin Stearate
The stearate salt of erythromycin, this oral antibiotic is absorbed in the intestine and converted to active erythromycin to treat bacterial infections. The stearate form helps mask the bitter taste of erythromycin in tablet formulations.
Peso Molecular
1018,4000 g/mol
TPSA
231,00 Ų
Áreas Terapêuticas
Mecanismo de Ação
Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
InChI
InChI=1S/C37H67NO13.C18H36O2/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;2-17H2,1H3,(H,19,20)/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;/m1./s1
Molecular Formula
C55H103NO15
HBD / HBA
6 / 16
Ligações Rotacionáveis
23
Átomos Pesados
71
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
The stearate salt of erythromycin, this oral antibiotic is absorbed in the intestine and converted to active erythromycin to treat bacterial infections. The stearate form helps mask the bitter taste of erythromycin in tablet formulations.
Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.
Yes, Erythromycin Stearate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200510. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 12559. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="erythromycin-stearate"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/erythromycin-stearate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/erythromycin-stearate/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/erythromycin-stearate/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="erythromycin-stearate"></drugfyi-drug>